BMY Q3 2024 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q3 2024 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.9B+8.4% YoY

Gross Profit

$6.6B55.6% margin

Operating Income

$2.3B19.2% margin

Net Income

$1.2B10.2% margin

EPS (Diluted)

$0.60

QoQ Revenue Growth

-2.5%

Cash Flow

Operating Cash Flow

$5.6B

Free Cash Flow

$5.3B

Stock-Based Comp.

$129M

Balance Sheet

Total Assets

$93.7B

Total Liabilities

$76.5B

Stockholders' Equity

$17.1B

Cash & Equivalents

$7.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.9B	$11.0B	+8.4%
Gross Profit	$6.6B	$6.2B	+6.4%
Operating Income	$2.3B	$2.1B	+8.7%
Net Income	$1.2B	$1.9B	-37.2%

Revenue Segments

Eliquis

$3.0B25%

Opdivo

$2.4B20%

Revlimid

$1.4B12%

Orencia

$936M8%

Pomalyst/Imnovid

$898M8%

Yervoy

$642M5%

Reblozyl

$447M4%

Other Growth Brands

$433M4%

Sprycel

$290M2%

Abraxane

$253M2%

Opdualag

$233M2%

Other Legacy Brands

$225M2%

Breyanzi

$224M2%

Camzyos

$156M1%

Zeposia

$147M1%

Abecma

$124M1%

Sotyktu

$66M1%

Krazati

$34M0%

Geographic Segments

UNITED STATES

$8.2B69%

Rest Of World

$3.4B28%

Other Region

$271M2%